News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Biggest Study Yet Backs GlaxoSmithKline (GSK) (Jobs) Cervical Cancer Shot



6/28/2007 2:54:09 AM

LONDON (Reuters) - GlaxoSmithKline Plc's experimental vaccine Cervarix has proved more than 90 percent effective in preventing precancerous lesions due to two types of a virus responsible for most cases of cervical cancer. Interim results from the biggest cervical cancer vaccine trial to date, published on Thursday in the Lancet medical journal, confirm previous promising data. Cervarix is a rival to Merck & Co. Inc.'s similar product Gardasil.

Read at Reuters


comments powered by Disqus
Reuters
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES